Reference pricing will follow failed price negotiations in Germany
This article was originally published in Scrip
Executive Summary
Companies in Germany that fail to negotiate a price discount with health insurers for their new drugs will see their products become subject to a reference pricing system that looks at prices in the 80% of European markets that are most comparable to Germany in terms of GDP.